TrialNeurogastroenterology and motility2022

Efficacy and safety of vibegron for the treatment of irritable bowel syndrome in women: Results of a randomized, double-blind, placebo-controlled phase 2 trial.

Brian E Lacy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.